MedTrace Logo

Non Motors Aspects in De Novo Parkinson's Disease

NCT02786667 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2017-10-26

No results posted yet for this study

Summary

Clinical description and pathophysiological study of recently diagnosed untreated patients with Parkinson's Disease.

Effect of a dopamine agonist (rotigotine) on apathy in de novo patients with Parkinson disease: A controlled, randomized, double blind study.

Conditions

  • Parkinson Disease
  • Apathy

Interventions

DRUG

Rotigotine

6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month

DRUG

Placebo

6 months treatment with Placebo up to 8 mg per day with a titration period for one month

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Anna Castrioto, MD · University Hospital, Grenoble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2017-10-15
Completion
2017-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786667 on ClinicalTrials.gov